GSK Denied Quick Win In Flonase Antitrust Cases

Law360, New York (June 2, 2011, 7:44 PM EDT) -- GlaxoSmithKline PLC on Thursday lost a bid for summary judgment in three antitrust cases pending in Pennsylvania that allege the company delayed sales of a generic version of Flonase by filing baseless petitions with the U.S. Food and Drug Administration.

The lawsuits brought by classes of direct and indirect Flonase purchasers and generics maker Roxane Laboratories Inc. claim that GSK stymied the release of the generic of Flonase, fluticasone propionate, by filing multiple “citizen petitions” with the FDA shortly before the company’s exclusive marketing rights for...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

AMERICAN SALES COMPANY, INC. v. SMITHKLINE BEECHAM CORPORATION


Case Number

2:08-cv-03149

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

ANITA B. BRODY

Date Filed

July 3, 2008


Case Title

IBEW - NECA LOCAL 505 HEALTH & WELFARE PLAN v. SMITHKLINE BEECHAM CORPORATION


Case Number

2:08-cv-03301

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

ANITA B. BRODY

Date Filed

July 14, 2008


Case Title

ROXANE LABORATORIES, INC. v. SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE


Case Number

2:09-cv-01638

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

ANITA B. BRODY

Date Filed

April 17, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.